<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01955980</url>
  </required_header>
  <id_info>
    <org_study_id>12082.102</org_study_id>
    <nct_id>NCT01955980</nct_id>
  </id_info>
  <brief_title>Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis</brief_title>
  <official_title>A Pilot Study to Investigate the Potential of Buparid/PARI SINUS Versus Budes® Nasal Spray to Avoid or Postpone Sinus Surgery in Adult Patients With Chronic Rhinosinusitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pari Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pari Pharma GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study should create data for the selection of a clinically relevant endpoint to assess
      the potential of Buparid/PARI SINUS to postpone sinus surgery in patients with chronic
      Rhinosinusitis.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Avoidance or postponing of sinus surgery</measure>
    <time_frame>From baseline to week 48</time_frame>
    <description>Time to surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Health-related quality of life</measure>
    <time_frame>From baseline to week 48</time_frame>
    <description>Assessments will be done using the Sino-Nasal outcome Test 22 (SNOT 22)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal obstruction</measure>
    <time_frame>8 weeks</time_frame>
    <description>Rhinomanometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation of the nasal mucosa and paranasal sinus</measure>
    <time_frame>Changes from Baseline at Week 8</time_frame>
    <description>Determination of the thickness of the mucosa using Magnetic Resonance Imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessment</measure>
    <time_frame>48 weeks</time_frame>
    <description>Treatment-emergent adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Rhinosinusitis</condition>
  <arm_group>
    <arm_group_label>Buparid; Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Buparid 1mg budesonide/2 ml nebulizer solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Budes; Treatment B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Budes Nasal Spray 50 µg budesonide/pump</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <description>Inhalation</description>
    <arm_group_label>Buparid; Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <description>Nasal Spray</description>
    <arm_group_label>Budes; Treatment B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with confirmed diagnosis of chronic rhinosinusitis

          -  Patient without alternative other than sinus surgery

          -  Patient's written informed consent obtained prior to any screening or study-specific
             procedure

          -  Male or female, ≥ 18 years of age

          -  Patient is able to undergo nasal therapy without restrictions

          -  Capable to correctly use the PARI SINUS device

          -  Capable of understanding the purpose and risk of the clinical trial

          -  Female patients with childbearing potential must have a negative urine pregnancy test
             prior to first IMP administration.

          -  Patient is able to participate in the study according to Investigator's opinion

        Exclusion Criteria:

          -  Patients with cystic fibrosis

          -  Patients with polyposis nasi grade I-IV

          -  Patients with prior FESS (Functional Endoscopic Sinus Surgery)

          -  Pregnant or breastfeeding women

          -  Any active invasive bacterial, viral or fungal infection within one week prior to
             first investigational medicinal product (IMP) administration

          -  No clinically relevant abnormal parameters of vital signs, blood biochemistry or
             renal/hepatic function

          -  Unlikely to comply with visits, inhalation procedures or other measurements scheduled
             in the protocol

          -  Receipt of an investigational drug as part of a clinical trial within 4 weeks prior to
             first administration of IMP

          -  Any co-existing medical condition that in the Investigator's judgement will
             substantially increase the risk associated with the patient's participation in the
             clinical trial

          -  Psychiatric disorders or altered mental status precluding understanding of the
             informed consent process and/or completion of the necessary procedures

          -  Drug or alcohol abuse

          -  End-stage malignancies

          -  Known hypersensitivity to Budesonide

          -  Patients with oral steroid therapy within the last 3 months

          -  Patients needing &gt; 1 mg/day Budesonide (or steroidal equivalent) for therapy of asthma

          -  Patients on therapy with leukotriene-receptor antagonists, decongestants,
             antihistamines or antibiotics

          -  Patients with frequent epistaxis (&gt; 1 episode per week)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Canis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Goettingen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNIVERSITÄTSMEDIZIN der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Munich</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2013</study_first_submitted>
  <study_first_submitted_qc>October 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2013</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CRS</keyword>
  <keyword>without polyposis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

